-Are CROs "necessary evil" partners or overhyped money machines — and what does ICON's 50% stock plunge really tell us about the state of clinical research?

In this Sticky Notes episode of Note to File, we riff on everything from conferences and culture to credibility and regulation in our industry, including:

-ICON's revenue overstatement and the brutal market reaction -What a 2% revenue error really means for trust, transparency, and CRO credibility -The strange love/hate dynamic around CROs on LinkedIn, Reddit, and in the trenches -How health system execs still don't really "get" research — and why that matters -The massive gap between research professionals and healthcare executives at conferences like VIVE and Scope -Whether the FDA could streamline oversight for low-risk trials without new legislation -Why risk-based monitoring and "common sense" regulation still haven't truly shown up at the site level -The paradox of an industry that bets billions on long-shot drugs but is terrified of operational innovation -Sponsors as the real power center: why nothing changes until sponsors want it to

If you're a site, sponsor, CRO, or just a research nerd trying to make sense of where this industry is headed, this one's for you.